Product ID: SQMIG35I2199
Report ID:
SQMIG35I2199 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
62 |
Figures:
77
Due to the significant presence of major players and the rising prevalence of multiple sclerosis, North America currently controls the majority of the global market for multiple sclerosis. Companies like Novartis AG, Sanofi SA, and Biogen have established significant market positions in the United States and are consistently putting more emphasis on launching new medications. According to the National Multiple Sclerosis Society, Canada has the highest MS prevalence rate in the world (291 per 100,000). According to the National MS Society, there are 1 million or so MS patients in the United States.
Due to the high prevalence of unmet demands and the quickly growing healthcare infrastructure, Asia-Pacific is predicted to present attractive potential in the market for multiple sclerosis. To take advantage of the development potential, key businesses are signing deals with regional medicine producers. As an illustration, Teva Pharmaceuticals and Takeda Pharmaceuticals reached an agreement to work together on the distribution of Copaxone in Japan. Currently, multiple sclerosis is treated with the immunomodulator drug copaxone.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35I2199